NeuroSearch Experimental Obesity Drug to Begin Phase 3 Trials
Source: http://feedproxy.google.com/~r/bullishbankers/~3/uoDGqhWNtQA/Posted on Sunday, June 14th, 2009 | In Financial, Market Commentary
As a trio of U.S. small-cap drug makers await crucial Phase 3 results later this year; NeuroSearch [NEUR: 0.00, N/A (N/A)] [NEUSF: 0.00, N/A (N/A)] is preparing to advance its own experimental weight loss drug to the final stage of clinical development following a successful End of Phase 2 meeting with the FDA which was announced earlier this week. Arena Pharma [ARNA: 4.99, +0.09 (+1.84%)], Vivus [VVUS: 6.04, +0.23 (+3.96%)], and Orexigen Therapeutics [OREX: 4.02, +0.06 (+1.52%)] are all awaiting Phase 3 clinical trial data expected during 3Q09 for their experimental weight loss drugs to support NDA filings for FDA approval, which are summarized and tracked in the BioMedReports.com FDA Calendar.
On 6/8/09, NeuroSearch announced that it has successfully completed its End of Phase 2 meeting with the FDA for tesofensine, a monoamine reuptake inhibitor in development as a novel treatment for obesity (weight management). The FDA endorses the overall Phase 3 plan for tesofensine in obesity, including the filing of an NDA based on 12 months safety and efficacy data. NeuroSearch will now finalize Phase 3 preparations and an SPA (Special Protocol Assessment) request for submission to the FDA, while continuing discussions with potential license partners.
The main conclusions from the End of Phase II discussions with the FDA include the following: (1) The proposed dose regimen of 0.25 mg or 0.5 mg tesofensine daily in Phase III was endorsed. (2) The proposed pivotal Phase 3 program for tesofensine in weight management was endorsed by the FDA and will consist of four placebo-controlled clinical studies, comprising a total of approximately 5,700 obese patients with and without co-morbidities (such as Type 2 diabetes, hypertension and dislipidemia). (3) Two of the four trials are powered to show superior weight loss effectiveness for tesofensine compared to sibutramine (marketed as Reductil and Meridia). (4) The safety and efficacy assessment within and across the Phase 3 studies and the filing of the NDA for tesofensine for weight management based on 12 months data were also endorsed by the FDA.
Earlier results from a Phase II Proof of Concept study with tesofensine in obesity, TIPO-1, has shown a placebo-corrected average weight loss of approximately 10% after 24 weeks of daily treatment with 0.5 mg tesofensine. The results from TIPO-1 have been published in The Lancet (The Lancet, Volume 372, Issue 9653, Pages 1906-1913, 29 November 2008) with the conclusion that tesofensine produces a weight loss at least twice that of currently approved anti-obesity drugs. The safety data base for tesofensine includes more than 1,500 patients having been exposed to treatment with tesofensine and hereof more than 1,300 on relevant dosing.
- Mike Havrilla
Disclosure: None. This article is taken from the website BioMedReports with the permission of the original author. All questions regarding disclosure should be referred to the original author.
Last 5 posts by Bullish Bankers
- Boone Boosts Energtek - July 20th, 2009
- The Long and the Short of it All - July 15th, 2009
- The Banking System Is Sitting On It’s Hands - July 13th, 2009
- China Mobile: The Foreign Giant - July 12th, 2009
- McDonald’s New Angus Burger – A Green Shoot? - July 10th, 2009
3Q09;, Arena Pharmaceuticals Inc;, bullish bankers, Diabetes, Fda, Financial, hypertension, Market Commentary, Mike Havrilla, obesity, The Lancet;, TIPO;, treatment for obesity, United States
 About Bullish Bankers (http://www.bullishbankers.com)
Bullish Bankers is a financial market and economic community focused on delivering original opinion, analysis and headlines to readers on a daily basis. In an effort to form a lasting online presence, a collaboration of two separate blogs resulted in what you see here today. Moving forward, we aim to provide fresh insight into the financial markets with the launch of Bullish Bankers dot com. On June 10th 2008, founders Jim Regan and Santosh Sankar began discussing plans to create a new stock market and economic resource website to serve the public. After recruiting seven fellow finance students from The Smeal College of Business and The Pennsylvania State University, Bullish Bankers began to take shape with a solid foundation of financial knowledge and excitement. With a background in online entrepreneurship and design, Jim Regan designed the website and publishing platform from the ground up in order to effectively publish articles and updates to the blog. With an official launch in late July 2008, Santosh Sankar and Jim Regan act as the leading editors and oversee coverage across all 10 sectors that comprise the S&P 500. Together, they aim to provide consistent, quality information in order to help readers understand the state of the financial markets through educated and refreshing opinion. In addition, Jim and Santosh oversee the executive board of editors at Bullish Bankers dot com, which includes fellow students Charles Petredis, Ryan Savitz and Steve Murray. |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.